ABC | Volume 115, Nº2, August 2020

Letter to the Editor Fernandes et al. Risks of Media Coverage of Scientific Data Arq Bras Cardiol. 2020; 115(2):278-280 6. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. Covid-19DoesNotLeadtoa“Typical”AcuteRespiratoryDistressSyndrome. Am J Respir Crit Care Med. 2020. 7. Paranjpe I, Fuster V, Lala A,Glicksberg BS, Levin MA, Charney AW, et al, et al. Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19. J Am Coll Cardiol. 2020:S0735-1097(20)35218-9. 8. Atallah B, Mallah SI, AlMahmeed W. Anticoagulation in COVID-19. Eur Heart J Cardiovasc Pharmacother. 2020. 9. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID -19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol. 2020 Apr 30;pvaa-036. 10. Nascimento JHP, Gomes BFdO, Junior PnRdC, et al. COVID-19 and Hypercoagulable State: A New Therapeutic Perspective. Arq Bras Cardiol. 2020;114(5):829-33. 11. Gautret P, Lagier JC, Parola P, Huang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:105949. 12. Fernandes CJCS. Devemos abordar todos os pacientes com COVID-19 da mesma forma? J Bras Pneumol.2020;46(4):e20200218. This is an open-access article distributed under the terms of the Creative Commons Attribution License 280